TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04554875

Intervention type: DIAGNOSTIC_TEST
Intervention: A scoring system
Description: The scoring system was used to rate score patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: A scoring system
Description: The scoring system was used to rate score patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: A scoring system
Description: The scoring system was used to rate score patients.
Study: NCT03923413

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples for MP evaluation

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples for MP evaluation
Study: NCT01371851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin extended release
Description: initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxazosin extended release
Description: initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
Study: NCT02967627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incisional Negative Pressure Wound Therapy (iNPWT)
Description: Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Gauze Dressing
Description: In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
Study: NCT00374322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib 1500 mg (6 tablets) daily for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 tablets daily for 12 months
Study: NCT01356017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg, S-amlodipine 5mg
Description: Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg
Description: Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
Study: NCT02223234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emails and 4 Home Visits
Description: Weekly emails and 4 home visits with health educator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Monthly emails on child health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emails and 2 home visits
Description: Weekly emails and 2 home visits with health educator
Study: NCT01846130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Study: NCT02931734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate 2%
Description: Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate 2%
Description: Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate 2%
Description: Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate 2%
Description: Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
Study: NCT00689650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1540 nm fractional laser
Study: NCT01558154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbs
Description: Chinese herbs special for depression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Thought Imprint Psychotherapy under lower Resistance State

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Give magnetic stimulation at head
Study: NCT00755482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquamin F

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextran)
Study: NCT02962713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART with Equia
Description: Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART with Giomer Beautifil-Bulk Restorative
Description: Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
Study: NCT02137369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective serotonin re-uptake inhibitor
Description: Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination treatment (SSRI + CBT)
Description: study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination treatment (SSRI + CBT)
Description: study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
Study: NCT01357967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI monotherapy
Description: SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel XR adjunctive
Description: Quetiapine group:~seroquel XR 50mg Day 1 --\> 50mg Day 2 --\> 150mg Day 3 --\> 150mg Day 4 --\> adjustment usually at hs but can be daytime
Study: NCT03317600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intervention is a nerve block with Lidocaine 2% with Adrenaline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention is a placebo nerve block with isotonic saline
Study: NCT03986853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling under general anesthesia
Study: NCT04388020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field
Description: For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field
Description: For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
Study: NCT03460223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: conventional plus MSC or placebo treatment
Study: NCT01702753

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis
Study: NCT03413436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: at least one cycle adjuvant chemotherapy after esophagectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: at least one cycle adjuvant chemotherapy after esophagectomy
Study: NCT00778674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Study: NCT04160780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF
Description: sinus augmentation using L-PRf as sole graft material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF mixed with xenograft
Description: sinus augmentation using L-PRF mixed with xenograft as sole graft material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: xenograft
Description: sinus augmentation using xenograft as sole graft material
Study: NCT01237639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell Transfusion
Description: Transfusion of Red blood cells to based on daily complete blood count

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell Transfusion
Description: Transfusion of Red blood cells to based on daily complete blood count
Study: NCT00058123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Study: NCT03969654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERSONA Total Knee
Description: Primary Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERSONA Total Knee
Description: Primary Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard Total Knee
Description: Primary Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard Total Knee
Description: Primary Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Total Knee
Description: Primary Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Total Knee
Description: Primary Total Knee Arthroplasty
Study: NCT01771198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIMVASTATIN
Description: SIMVASTATIN tablet of 40mg once a day during 30 days
Study: NCT01212770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20 mg twice daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg twice daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03722368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCHC
Description: The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCHC+
Description: The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
Study: NCT02483169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: Cilostazol 100mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: Cilostazol 100mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: Probucol 250mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol 250mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of cilostazol
Description: same shape and size of active cilostazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of cilostazol
Description: same shape and size of active cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of aspirin
Description: same size and shape of active aspirin 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of aspirin
Description: same size and shape of active aspirin 100mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intima-medial thickness
Description: ultrasound measured IMT of both common carotid arteries

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intima-medial thickness
Description: ultrasound measured IMT of both common carotid arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intima-medial thickness
Description: ultrasound measured IMT of both common carotid arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intima-medial thickness
Description: ultrasound measured IMT of both common carotid arteries
Study: NCT03143985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
Study: NCT00740792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine HCl/fluticasone propionate
Description: azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine Hcl
Description: azelastine Hcl 548 mcg one spray per nostril BID
Study: NCT04364646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Integrated Chronotherapy
Description: Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Integrated Chronotherapy
Description: Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
Study: NCT01346826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard 2 hours-infusion
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accelerated 1 hour-infusion
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accelerated 30 minutes-infusion
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5.
Study: NCT02906150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin (Thymosin alpha 1, Ta1)
Description: Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC (chemotherapy and platinum agent)
Description: Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC (chemotherapy and platinum agent)
Description: Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Study: NCT02283060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: To be administered orally, once daily with food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: To be administered orally, once daily at bedtime on an empty stomach
Study: NCT01401751

Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglycemia-Hyperglycemia Minimizer System
Description: Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm